INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,636 | -17.7% | 89 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $5,635 | +16.9% | 89 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4,819 | +2.3% | 89 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,710 | -32.7% | 89 | -39.9% | 0.00% | -25.0% |
| Q3 2022 | $7,000 | -12.5% | 148 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $8,000 | 0.0% | 148 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $8,000 | +33.3% | 148 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $6,000 | 0.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,000 | +20.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 148 | -24.1% | 0.00% | -25.0% |
| Q4 2020 | $6,000 | +20.0% | 195 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $5,000 | +66.7% | 195 | -43.5% | 0.01% | +150.0% |
| Q3 2019 | $3,000 | -40.0% | 345 | -9.2% | 0.00% | -33.3% |
| Q2 2019 | $5,000 | 0.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q1 2019 | $5,000 | -44.4% | 380 | -3.8% | 0.00% | 0.0% |
| Q3 2018 | $9,000 | – | 395 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |